PFE
21
-2
NRG
67
8
CMA
53
3
MHK
46
3
BAC
39
3
ROK
42
4
HST
63
5
PCAR
56
7
V
56
2
PNR
69
6
FDX
41
11
AVB
54
9
CMS
57
3
BF.B
31
2
TJX
43
3
MDLZ
38
2
VZ
37
3
BK
69
4
KMI
69
4
BRK.B
27
2
PFE
21
-2
NRG
67
8
CMA
53
3
MHK
46
3
BAC
39
3
ROK
42
4
HST
63
5
PCAR
56
7
V
56
2
PNR
69
6
FDX
41
11
AVB
54
9
CMS
57
3
BF.B
31
2
TJX
43
3
MDLZ
38
2
VZ
37
3
BK
69
4
KMI
69
4
BRK.B
27
2
Financhill
Back

Autolus Therapeutics PLC 10K Form

Sell
48

AUTL
Autolus Therapeutics PLC

Last Price:
3.38
Seasonality Move:
1.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AUTL News And Ratings

See the #1 stock for the next 7 days that we like better than AUTL

AUTL Financial Statistics

Sales & Book Value

Annual Sales: $1.7M
Cash Flow: $-51.92M
Price / Cash Flow: 0
Annual Sales: $1.98
Price / Book: 1.7

Profitability

EPS (TTM): -1.17000
Net Income (TTM): $-233.98M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Autolus Therapeutics PLC Earnings Forecast

Key Autolus Therapeutics PLC Financial Ratios

  • The Research & Development expenses have been 7,684.39% of Revenue.
  • The Interest Expense is -21.63% of Operating Income.
  • The Net Earning history of AUTL is -12,272.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Autolus Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUTL
CUSIP: 05280R
Website: autolus.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AUTL Technical Analysis vs Fundamental Analysis

Sell
48
Autolus Therapeutics PLC (AUTL) is a Sell

Is Autolus Therapeutics PLC a Buy or a Sell?